Invesco Biotechnology & Genome ETF (PBE) Dividend Yield, History & Forecast

Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund (ETF) listed on the New York Stock Exchange Arca. It pays a current dividend yield of 1.63% ($1.55 per share annually (TTM)). The most recent ex-dividend date was June 22, 2026, with payment scheduled for June 26, 2026. market capitalization is approximately $283M. Review PBE dividend history on this scorecard, compare peers in the Compare Dividend Returns tool, or project income with the dividend calculator.

PBE fund composition

PBE holds 31 positions, with 47.0% of assets in its ten largest. It charges an expense ratio of 0.59%, and manages $417.1M.

Top 10 holdings

HoldingWeight
REGNRegeneron Pharmaceuticals Inc5.14%
RPRXRoyalty Pharma PLC5.13%
BIIBBiogen Inc5.07%
AMGNAmgen Inc5.06%
VRTXVertex Pharmaceuticals Inc5.06%
GILDGilead Sciences Inc5.05%
NTRANatera Inc4.85%
ILMNIllumina Inc4.76%
ALNYAlnylam Pharmaceuticals Inc3.50%
SRPTSarepta Therapeutics Inc3.36%

Sector allocation

Healthcare99.9%Financial Services0.1%Cash & Others0.0%

Frequently Asked Questions about Invesco Biotechnology & Genome ETF (PBE)

What is Invesco Biotechnology & Genome ETF's dividend yield?
Invesco Biotechnology & Genome ETF (PBE) pays a current trailing twelve-month dividend yield of 1.63%, which works out to $1.55 per share annually based on the most recent payout schedule.
When does Invesco Biotechnology & Genome ETF pay distributions?
The most recent ex-dividend date was June 22, 2026. The next scheduled dividend payment date is June 26, 2026.
How many years has Invesco Biotechnology & Genome ETF increased its dividend?
Invesco Biotechnology & Genome ETF (PBE) has increased its dividend for 2 consecutive years.
What does Invesco Biotechnology & Genome ETF invest in?
The Invesco Biotechnology & Genome ETF (PBE) seeks to replicate the performance of the Dynamic Biotech & Genome Intellidex Index. This fund typically allocates a minimum of 90% of its total assets to the securities comprising the underlying index. The Index is constructed to achieve capital appreciation by thoroughly evaluating companies based on several investment criteria, including their price momentum, earnings growth, overall quality, management decisions, and valuation. It consists of 30 U.S.-based companies within the biotechnology and genome sectors. These companies are primarily...